Expert Highlights ‘Exciting’ RCC Presentations From 2023 KCRS
Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.
Non-Immunotherapy Interventions May Successfully Target Renal Cell Carcinoma
A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Expert Describes Direct Tumor Killing Strategies in Renal Cell Carcinoma
Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Belzutifan Generates ‘Excitement’ in Renal Cell Carcinoma, Expert Says
Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.
Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell Carcinoma
In this installment of Clinical Quandaries, Justine Panian, BS, and colleagues present a case of a 60-year-old Mexican woman with fevers, abdominal pain, and hypertension.
Conclusions: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Brian Rini, MD, summarizes the thoughts of his colleagues on the use of lenvatinib plus pembrolizumab to treat advanced renal cell carcinoma.
The Exciting Future of Advanced Renal Cell Carcinoma Management
A panel of oncologists look at what’s in the pipeline for advanced renal cell carcinoma, including trials and treatment options.
Unmet Needs in Advanced Renal Cell Carcinoma Management
Two kidney cancer experts explore the current unmet needs for patients with advanced renal cell carcinoma.
Unmet Needs in the Front-Line Setting for Renal Cell Carcinoma
A look at the current unmet needs in front-line renal cell carcinoma treatment.
Patient Quality of Life on Lenvatinib plus Pembrolizumab Treatment for Renal Cell Carcinoma
Oncologists review quality of life data for patients with renal cell carcinoma receiving lenvatinib plus pembrolizumab combination treatments.
Dosing Lenvatinib for Treatment of Advanced Renal Cell Carcinoma
Kidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.
Dosing Lenvatinib for First-Line Renal Cell Carcinoma Treatment
An explanation of dosing strategies when treating patients with renal cell carcinoma in the first-line with lenvatinib.
Treating Favorable Risk Patients with Renal Cell Carcinoma with Lenvatinib
Experts discuss the safety of treating renal cell carcinoma with lenvatinib within different patient risk populations.
Risk Factors in the Management of Advanced Renal Cell Carcinoma
Possible comorbidities and other risk factors in advanced renal cell carcinoma that would affect potential treatment regimens.
Choosing a Combination Treatment for Advanced Renal Cell Carcinoma
A look at the factors considered in choosing an appropriate combination treatment for advanced renal cell carcinoma.
Choosing a First-Line Combination Treatment Regimen for Renal Cell Carcinoma
Drs Rana McKay and Tom Powles debate the merits of different first-line combination treatment regimens for renal cell carcinoma.
Incorporating Data from the CLEAR Trial into Clinical Practice
Experts discuss how data from the CLEAR trial affects the management of advanced renal cell carcinoma in their clinical practices.
Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma: Key Takeaways
Rana McKay, MD, and Tom Powles, MBBS, MRCP, MD, highlight key data from the CLEAR trial and offer their overall opinions on the combination of lenvatinib plus pembrolizumab for the treatment of renal cell carcinoma [RCC].
Impressions of Data and Results from the CLEAR Trial
Oncologists give their initial impressions about the results of a clinical trial studying doublet combination therapies for advanced renal cell carcinoma.
Background: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer, MD, presents data examined in the article, “Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.”
Redefining the Clinical States of Prostate Cancer in the Modern Era
Rana R. McKay, MD, reflects on a proposal from her colleagues regarding a new model for guiding the treatment of prostate cancer that focuses on a “transitional” disease state.
Rana R. McKay, MD, on the Impact of the Phase II OMNIVORE Trial
The expert from the University of California San Diego discusses the importance of the findings presented at the 2020 ASCO Virtual Scientific Program
Prostate Cancer 2012: Where Do We Stand and Where Are We Heading?
Recent progress in our understanding of the pathogenesis of advanced prostate cancer has heralded a new era in treatment. Numerous agents now populate the treatment landscape, and an impressive number of novel agents are in development. However, many questions remain unanswered, paving the path for discovery in the future.
2 Clarke Drive Cranbury, NJ 08512